Home │中文 │English │ UBI │ UBIA │ UBIOCMO
    • Message from Chairperson
    • Company Overview
    • History
    • Management Team
    • Board of Directors
    • Corporate Responsibility
    • Core Technologies
    • Pipelines
    • Products
    • Manufacturing Facilities
    • Contract Manufacturing Services
    • Contract Research & Development Services
    • Press Release
    • Media & News
    • Events
    • Presentations
    • Chairperson’s Daily Digest
    • Shareholder Services
    • Material information
    • Investor Conference
    • Corporate Governance
    • Locations
    • Contact Us
    • Careers
    • Links
 
    Press Release
  • Media & News
  • Events
  • Presentations
  • Chairperson’s Daily Digest
• UBIA Group and Development Center of Biotechnology Co-Develop a New Targeted Cancer Therapy Drug(2016/02/18)
• UBIP Emerging Stock Board Pre-Listing Presentation is Held Today (2016/1/21)
• Phase I Clinical Summary Report of UBIP’s EPO Biosimilar was Approved by Taiwan FDA (2016/01)
• UBIP Honored by Taiwan President Ma for New Drug Development and Branding (2015/12/30)
• Phase III Clinical Trial for EPO Biosimilar UB-851 is Approved to Proceed by Taiwan FDA (2015/12)
• UBIP Awarded the First Prize of Outstanding Enterprise, the 12th National Brand Yushan Award ( 2016/11/05 )